Alamar Biosciences Delivers 82% Revenue Growth in Q2, Guides for 59% Full-Year Expansion
ALMR sits 49% above its 52-week low of $18.845.
Summary
Alamar Biosciences posted Q2 revenue of $29.4M (+82% YoY) and guided for full-year 2026 revenue of $116M–$120M, representing 59% growth at the midpoint. Consumable revenue nearly tripled, and gross margin improved to 60%.
Key Events · Earnings and Guidance · ALMR
-
Q2 Revenue Surges 82%
Driven by a 147% jump in consumable revenue to $15.5 million, total revenue reached $29.4 million, up from $16.2 million in Q2 2025.
-
Full-Year 2026 Guidance Initiated
Management expects full-year revenue of $116–$120 million, representing 59% growth at the midpoint compared to 2025.
-
Gross Margin Expands to 60%
Reflecting manufacturing efficiencies and a favorable shift toward high-margin consumables, gross margin improved from 53% a year ago.
-
Strong Cash Position
Cash, equivalents, and short-term investments totaled $256.3 million as of June 30, 2026, providing substantial runway for growth investments.
Analysis · ALMR · Industrial Applications And Services
A standout second quarter saw revenue climb 82% to $29.4 million, fueled by a 147% surge in consumable sales. Gross margins expanded to 60%, and the company introduced full-year 2026 revenue guidance of $116–$120 million, implying 59% growth at the midpoint. While operating losses widened on planned investments, the $256.3 million cash position provides ample runway. Together, the results and outlook underscore the commercial momentum of the NULISA platform and the recent launch of high-value panels like eMTBR-tau and Immune 340.
At the time of this filing, ALMR was trading at $27.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.85 to $29.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.